Amide Compounds for Multi-Disease CSF-1R Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel type III tyrosine kinase receptor inhibitors, particularly CSF-1R inhibitors, to treat diseases such as cancer, autoimmune diseases, and inflammatory diseases, as existing inhibitors may not adequately address these conditions.
Innovation Solution
Development of amide compounds of formula (I) and their pharmaceutically acceptable salts, deuterates, solvates, racemic mixtures, enantiomers, and diastereomers, which can inhibit CSF-1R activity in vivo or in vitro, and are used in pharmaceutical compositions for treating various diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CSF-1R inhibitors are used, then some therapeutic effect is achieved, but they do not adequately treat all disease conditions including cancer, autoimmune diseases, and inflammatory diseases
Solution Approach 1:
The patent develops compound (I) as a universal CSF-1R inhibitor that can treat multiple disease types including cancer, autoimmune diseases, and inflammatory diseases. The compound is designed to inhibit CSF-1R activity across different pathological contexts, making it applicable to diverse conditions that require modulation of the CSF-1R signaling pathway.
2Adaptability or versatility
If novel amide compounds of formula (I) are developed, then broader disease treatment capability is achieved, but compound structure complexity increases
Solution Approach 1:
The compound (I) structure is segmented into distinct functional modules: a heterocyclic core structure (X, Y1, Y2, Y3), substitutable R groups (R1-R9), and variable linkers (L, W, n). This modular segmentation allows systematic optimization of each component to achieve broad disease coverage while maintaining reasonable structural complexity through defined building blocks.
Solution Approach 2:
The patent employs parameter changes by varying substituents R1-R9, heterocyclic types (X, Y1, Y2, Y3), and linker configurations (L, W, n) to optimize compound activity across different disease indications. This systematic parameter variation enables tuning of pharmacological properties to address multiple disease conditions without requiring entirely new molecular frameworks.
3Reliability
If CSF-1R inhibition is enhanced to reduce tumor growth and macrophage activity, then therapeutic benefit increases, but potential side effects may increase
Solution Approach 1:
The patent utilizes feedback mechanisms through in vitro and in vivo assays to evaluate CSF-1R inhibition efficacy and macrophage activity modulation. By measuring actual biological responses (tumor growth reduction, macrophage activity changes), the compound structure can be iteratively optimized to maximize therapeutic benefit while monitoring and controlling potential harmful effects.
Data Source
AI summary
The present invention relates to novel amide compounds of formula (I), pharmaceutical compositions comprising same, methods for preparing same, and uses thereof, wherein the definition of each symbol is as described in the description.